Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Market Commentary — 7999 total
Options markets are pricing in a busy week. Earnings-driven names dominate the expiry calendar as traders stack near-term bets ahead of key prints. Micron Technology reports this week with a dense expiry ladder. Six…
FedEx, Micron, and Carnival headline a busy week of corporate earnings. No major IPOs are on the calendar for the next seven days. Today and Tomorrow Monday June 23 brings the first wave. FedEx reports Q4 2026 results…
ACN took a double hit today. Analysts first downgraded the IT services giant, then cut the consensus target price to $203.82 from $227.74. That is a drop of roughly $24 per share. The $95.8 billion company now has…
Insiders at AGX and AMAT filed a wave of large sell trades this week, with filings landing as recently as June 17. Argan leads the pack. AGX Chairman William Griffin filed a $32.2M sale on June 16. The stock was priced…
Iran-Israel tensions are easing. The Strait of Hormuz is reopening after a deal to end the conflict. Oil markets have shifted focus from shortage fears to looming supply gluts. That headline dominated financial media…
A busy earnings calendar is shaping options positioning this week. Micron Technology and FedEx head a slate that includes Datadog and Albemarle. Traders are loading up on near-term expiries. MU has the most active…
FedEx, Carnival, and KB Home all report on Monday, June 23. The trio covers freight, travel, and housing — a broad read on the US economy. FedEx Q4 results land after the close. Investors want clarity on volumes and…
Analyst sentiment shifted sharply on Thursday. Three names stand out from a busy round of rating changes. ACN took the hardest hit. Accenture was downgraded at the consensus level. The average analyst target price…
Applied Materials CEO Gary Dickerson filed multiple stock sales this week worth a combined ~$36M. The trades were reported June 17 and covered sales between June 15–16 at prices around $590–$597 per share. The…
Short sellers have been busy this week. SHAZ saw the biggest weekly jump among mid-caps. Its short interest as a percentage of free float leapt from 12.4% to 50.7% in just seven days — a 38-point surge. WOLF…
Oil is the session's biggest story. Options markets flooded with energy bets as traders position around an Iran-crisis-driven supply shock. CVX and XOM are in focus. OXY also drew heavy options flow. FT headlines…
Iran's conflict with Israel shook oil markets this week. That sent options traders rushing into energy names — and the signals are worth watching closely. XOM and CVX both carry dense expiry calendars through…
The week of June 18–25 brings a packed earnings schedule. Three marquee names dominate the calendar. FDX kicks things off Monday. FedEx reports Q4 2026 results after the close on June 23. The logistics giant is a key…
Scotiabank made the boldest call of the day. Analyst Patrick Colville raised his target on DDOG from $225 to $275. That is a 22% jump. He maintained his Buy rating on the cloud monitoring firm, which carries a $75B…
A wave of insider selling hit AMAT this week. CEO Gary Dickerson and at least five other executives filed 22 separate sell transactions on June 17. Combined, they offloaded over $80 million in shares at prices around…
Short sellers made bold moves this week. SHAZ (SharonAI Holdings) saw the biggest jump — SI % of Free Float rocketed from 12.4% to 50.7% in just seven days, a 38-point surge. Availability stands at just 3.6%, meaning…
Super Micro Computer surged Thursday, topping the high-impact news lists across multiple sources. The server maker joins a broader chip rally that has been building all week. MACOM Technology Solutions was featured…
Three high-profile reports arrive before Friday. The week's biggest event is MU on Wednesday. Micron Technology carries a $1.18 trillion market cap into its Q3 results. Analysts will focus on AI-driven memory demand…
Micron Technology grabbed headlines Wednesday after Rosenblatt analyst Kevin Cassidy doubled his price target to $1,200. That is up from $600 — a move that dwarfs anything else on the analyst tape this session. Cassidy…
Insider filings this week paint a split picture. Executives and major shareholders are pulling cash out of tech giants. But at one biotech, the CEO just made a massive bet on his own company. Summit Therapeutics CEO…
